Haematologica, Vol 94, Issue 8, 1085-1093 doi:10.3324/haematol.2008.001149
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toffalini, F.
Right arrow Articles by Demoulin, J.-B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toffalini, F.
Right arrow Articles by Demoulin, J.-B.

Myeloproliferative Neoplasms

The fusion proteins TEL-PDGFRβ and FIP1L1-PDGFR{alpha} escape ubiquitination and degradation

Federica Toffalini1, Anders Kallin1, Peter Vandenberghe3, Pascal Pierre4, Lucienne Michaux2,3, Jan Cools3,5, Jean-Baptiste Demoulin1

1 Université Catholique de Louvain, de Duve Institute, Brussels
2 Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels
3 Center for Human Genetics, K.U. Leuven, Leuven
4 Cliniques du Sud-Luxembourg, Site Clinique Saint-Joseph, Arlon
5 Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium

Correspondence: Jean-Baptiste Demoulin, Université Catholique de Louvain, de Duve Institute, Unité MEXP - UCL 74.30, avenue Hippocrate 75, BE-1200 Brussels, Belgium. E-mail:jb.demoulin{at}uclouvain.be

Background: Chimeric oncogenes encoding constitutively active protein tyrosine kinases are associated with chronic myeloid neoplasms. TEL-PDGFRβ (TPβ, also called ETV6-PDGFRB) is a hybrid protein produced by the t(5;12) translocation, FIP1L1-PDGFR{alpha} (FP{alpha}) results from a deletion on chromosome 4q12 and ZNF198-FGFR1 is created by the t(8;13) translocation. These fusion proteins are found in patients with myeloid neoplasms associated with eosinophilia. Wild-type receptor tyrosine kinases are efficiently targeted for degradation upon activation, in a process that requires Cbl-mediated monoubiquitination of receptor lysines. Since protein degradation pathways have been identified as useful targets for cancer therapy, the aim of this study was to compare the degradation of hybrid and wild-type receptor tyrosine kinases.

Design and Methods: We used Ba/F3 as a model cell line, as well as leukocytes from two patients, to analyze hybrid protein degradation.

Results: In contrast to the corresponding wild-type receptors, which are quickly degraded upon activation, we observed that TPβ, FP{alpha} and the ZNF198-FGFR1 hybrids escaped down-regulation in Ba/F3 cells. The high stability of TPβ and FP{alpha} hybrid proteins was confirmed in leukocytes from leukemia patients. Ubiquitination of TPβ and FP{alpha} was much reduced compared to that of wild-type receptors, despite marked Cbl phosphorylation in cells expressing hybrid receptors. The fusion of a destabilizing domain to TPβ induced protein degradation. Instability was reverted by adding the destabilizing domain ligand, Shield1. The destabilization of this modified TPβ reduced cell transformation and STAT5 activation.

Conclusions: We have shown that chimeric receptor tyrosine kinases escape ubiquitination and down-regulation and that their stabilization is critical to efficient stimulation of cell proliferation.

Key words: PDGF receptor, oncogenes, protein degradation, ubiquitin.